Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Dublin, Aug. 11, 2017 -- The "Seasonal Influenza Vaccines" report has been added to Research and Markets' offering.
Seasonal influenza is an acute viral infection that is spread by person-to-person transmission. Influenza, commonly referred to as the flu, circulates worldwide and can affect anyone in any age group, although annual epidemics peak during winter in temperate climates. Seasonal influenza can be type A, B, or C. Type A influenza viruses are considered to be the most virulent of the three types and can be further classified by serotype based on antibody response to the virus.
Seasonal influenza presents significant public health problems for nearly every country, largely because of the cost associated with the treatment or management of the disease, as well as the toll on the workforce. Vaccination against seasonal influenza is the most effective method of preventing influenza infection. However, global vaccination rates remain lower than the levels recommended by the World Health Organization.
Recent events and opinion:
- Quadrivalent vaccines are seeing rapid uptake and will gradually replace trivalent vaccines in all patient groups in the US and EU markets
- The broadening of recommendations to include school-aged children will drive EU market growth significantly
- Adjuvanted vaccines in development have the potential to address unmet needs in infants and the elderly
Key Topics Covered:
Forecast: Seasonal Influenza Vaccines
Executive Summary
- Market Overview and Trends
- Key Drivers and Resistors of Conversion to QIVs
- Market Definition
- US Market Forecast
- France Market Forecast
- Germany Market Forecast
- Italy Market Forecast
- Spain Market Forecast
- UK Market Forecast
Marketed Drugs: Seasonal Influenza Vaccines
- Executive Summary
- Product Overview
- Product profile: FluMist QIV
- Product profile: Flucelvax QIV
- Product profile: Fluzone High-Dose
Pipeline: Seasonal Influenza Vaccines
- Executive Summary
- Clinical Pipeline Overview
- Product profile (late stage): Fluad QIV
For more information about this report visit https://www.researchandmarkets.com/research/gz6m4x/seasonal
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Vaccines
